ABBV Jan 2024 145.000 put
| Previous close | 2.6400 |
| Open | 2.1500 |
| Bid | 1.8600 |
| Ask | 1.9300 |
| Strike | 145.00 |
| Expiry date | 2024-01-19 |
| Day's range | 1.6800 - 2.2200 |
| Contract range | N/A |
| Volume | |
| Open interest | 3.83k |
- PR Newswire
New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) announced today that adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) previously treated with two or more prior therapies experienced strong and durable responses with high overall response (ORR) and complete response (CR) rates when treated with epcoritamab (DuoBody® CD3xCD20), an investigational, subcutaneously administered T-cell engaging bispecific antibody. More than half of patients who responded to treatment in the st
Motley Fool3 Dividend Stocks You Can Safely Hold for Decades
Remember Montgomery Ward, Lehman Brothers, and Pan Am? Investors who bought those stocks counting on receiving steady dividends throughout their lifetimes were sorely disappointed. Here are three dividend stocks that you can safely hold for decades.
Motley FoolBetter Dividend Stock: AbbVie vs. Medical Properties Trust
AbbVie (NYSE: ABBV), the pharmaceutical giant behind the top-selling drug of the past decade, and Medical Properties Trust (NYSE: MPW), a real estate investment trust (REIT) that focuses on hospitals, both offer dividend yields that are way above average. AbbVie is a Dividend King that has raised its quarterly payout a whopping 288% since spinning off from Abbott Laboratories in 2013.
